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Introduction
Mirabegron, a selective b3-adrenoreceptor agonist,
is a well-established alternative to antimuscarinics
in adults with overactive bladder (OAB) symptoms
and is under development for use in pediatric
patients. Understanding drug pharmacokinetics (PK)
in pediatric patients is needed to determine appro-
priate dosing. Conducting these studies is ethically
complex, particularly as regulatory guidance re-
quires that PK is assessed in pediatric patients with a
therapeutic need for the drug. It is also vital to
evaluate the safety/tolerability and palatability/
acceptability of pediatric formulations.
Purpose
The purpose of the study was to characterize the PK
of mirabegron in pediatric patients with neurogenic
detrusor overactivity or idiopathic OAB, to provide a
basis for a weight-based dosing algorithm, and to
evaluate the safety, tolerability, and palatability/
acceptability of the formulations.
Materials and methods
A preliminary population PK model constructed from
adult data with allometric scaling was used to pre-
dict single weight-adjusted mirabegron doses. This
was developed to achieve exposures in pediatric
patients in two phase 1 studies that were consistent
with steady state in adults following once-daily
25 mg (‘low dose’) and 50 mg (‘high dose’) dosing. In
study 1, adolescents (12e<18 years) and children
(5e<12 years) received a single tablet under fed ore study.
rol.2019.10.009
s). Published by Elsevier Ltd on behalf of Journal of Ped
e (http://creativecommons.org/licenses/by-nc-nd/4.0/fasted conditions. In study 2, children (3e<12 years)
received a single oral suspension dose under fed
conditions. The PK data were used to assess the
predictive value of the preliminary PK model and to
update it to analyze mirabegron PK in pediatric pa-
tients. The safety/tolerability and palatability/
acceptability of the formulations were evaluated.
Results
Forty-three patients comprised six study cohorts:
adolescents, low-dose tablets, fed (nZ 7); children,
low-dose tablets, fed (n Z 7); adolescents, high-
dose tablets, fed (n Z 8); children, high-dose tab-
lets, fed (n Z 6); children, high-dose tablets, fasted
(nZ 6); and children, high-dose oral suspension, fed
(n Z 9). The population PK modelebased doses for
tablets and oral suspension achieved exposures that
were typically consistent with steady state in adults.
The final population PK model was used to describe
the PK for mirabegron in pediatric patients (Table).
Both formulations were well tolerated, and there
were no reports of bad taste or swallowing diffi-
culties for the tablets, although some found the oral
suspension unpleasant.
Conclusions
The single, weight-adjusted pediatric mirabegron
doses were successfully predicted by population PK
modeling to achieve drug exposures comparable
with steady state in adults. The finalized PK model
used to characterize the pediatric PK of mirabegron
will be utilized to develop a weight-based dosing
algorithm. The single mirabegron doses were well
tolerated.iatric Urology Company. This is an open access article
).
Summary Table Pharmacokinetic parameters of mirabegron by cohort.





































AUCinf, ng$h/mL 103 (83.7e158) 117 (80.6e208) 411 (150e573) 422 (288e715) 883 (724e1200) 537 (199e670)
Cmax, ng/mL 3.85 (2.45e10.5) 5.24 (2.45e14.9) 29.7 (3.40e80.4) 38.1 (14.1e98.2) 58.4 (28.6e79.2) 16.7 (2.56e42.4)
tmax, h 5.03 (3.95e5.75) 4.17 (2.55e6.37) 4.48 (3.08e7.08) 4.28 (3.88e4.42) 3.95 (3.47e4.27) 3.93 (1.25e6.50)
t1/2, h 45.0 (41.1e48.7) 44.5 (40.7e50.1) 42.7 (40.5e54.0) 42.2 (39.3e45.2) 43.0 (42.0e52.9) 42.7 (39.4e65.2)
CL/F, L/h 248 (158e320) 214 (120e310) 158 (131e333) 118 (70.0e174) 59.2 (41.7e97.7) 186 (146e502)
AUC24, ng$h/mL 49.7 (40.2e76.1) 56.3 (38.8e100) 198 (72.2e275) 203 (138e344) 424 (348e577) 258 (95.7e322)
Data shown are median (range).
AUC24 Z area under the concentrationetime curve from 0 to 24 h, AUCinf Z area under the concentrationetime curve from 0 to infinity,
CL/F Z apparent oral plasma clearance, Cmax Z maximum concentration of drug after administration, tmax Z time at which Cmax
occurred, t1/2 Z half-life.
31.e2 S. Rittig et al.Introduction
Overactive bladder (OAB) syndrome affects 12% of chil-
dren aged 5e10 years [1,2]. Neurogenic detrusor over-
activity (NDO) is defined by involuntary detrusor
contractions during filling cystometry in patients with a
relevant neurological condition [2]. Pharmacotherapy op-
tions for pediatric patients with OAB symptoms or NDO are
limited to antimuscarinics [1,3,4], although few clinical
trials have been conducted [4e10]. Mirabegron, a b3-
adrenoreceptor agonist, is an alternative to anti-
muscarinics in adults with OAB symptoms although data in
pediatric patients are limited [11e15].
Understanding drug pharmacokinetics (PK) in pediatric
patients is needed to determine appropriate dosing. How-
ever, the conduct of phase 1 PK studies in pediatric patients
is ethically complex, particularly as drug safety in this
population is often unconfirmed and as numerous blood
samples may be required. In contrast with PK studies in
healthy adults, regulatory guidance requires that PK is
assessed in pediatric patients with a therapeutic need for
the drug [16e18], which may necessitate normal medica-
tion interruption.
By using population PK modeling to determine PK pa-
rameters from sparse data [19e22], the phase 1 mirabegron
pediatric studies could be conducted by administering a
single dose to a small number of patients with limited blood
sampling. Mirabegron PK data from adults permitted
development of a preliminary PK model with allometric
scaling, which was used to predict the single, weight-
adjusted pediatric doses of mirabegron tablets and oral
suspension required to achieve equivalent exposures to
adults at steady state.
The purpose of the two phase 1 pediatric studies re-
ported herein was to assess the safety and tolerability of
mirabegron tablets and oral suspension, obtain PK data to
confirm the predictive value of the preliminary PK model,
and update the model to describe the pediatric PK ofmirabegron. The palatability and acceptability of the two
formulations were also evaluated.Materials and methods
Study design
Two multicenter, open-label, single-dose phase 1 mirabe-
gron studies were conducted in children and adolescents
with NDO or idiopathic OAB. The studies were conducted in
accordance with European Union recommendations [18]
(patients had the indication to be treated with no induce-
ment to enter the study for the patients or their parents/
legal guardians). In study 1 (NCT02211846), children
(5e<12 years) and adolescents (12e<18 years) with a
diagnosis of NDO or idiopathic OAB according to Interna-
tional Children’s Continence Society (ICCS) criteria [2]
received a single mirabegron prolonged-release tablet. The
study was conducted at nine centers from September 2014
to September 2015. In study 2 (NCT02526979), children with
a diagnosis of NDO (3e<12 years) or idiopathic OAB (5e<12
years) according to ICCS criteria [2] received a single mir-
abegron dose using prolonged-release oral suspension. The
study was conducted at three centers from December 2015
to December 2016. As the two studies had consistent
methodology, data are reported collectively. Inclusion/
exclusion criteria are provided in Supplementary Table 1.
Patients were enrolled into six cohorts, with the safety
data from each cohort being reviewed before enrollment
into the next cohort: adolescents, low-dose tablets, fed;
children, low-dose tablets, fed; adolescents, high-dose
tablets, fed; children, high-dose tablets, fed; children,
high-dose tablets, fasted; and children, high-dose oral
suspension, fed. Cohorts 1e5 were from study 1, and cohort
6 was from study 2. Cohort 5 was included to assess mir-
abegron safety at the higher exposure expected while
fasting.
The pharmacokinetics of mirabegron in children and adolescents 31.e3Screening occurred 28 days before dosing, with a
subsequent washout of prohibited medications, if appli-
cable (Supplementary Fig. 1). Before day 1, patients were
asked to fast from midnight. Cohorts 1e4 and 6 received a
light breakfast (low in fat and fiber) and were dosed within
1 h. Patients in cohort 5 remained fasted.
Patients were dosed according to body weight. Patients
in the low-dose tablet cohorts weighing 20e<55 or 55 kg
received 25 or 50 mg, respectively. Patients in the high-
dose tablet cohorts weighing 20e<40 or 40 kg received 50
or 75 mg (25 þ 50 mg tablets), respectively. Patients in the
oral suspension cohort weighing 15e<20, 20e<30,
30e<40, or 40 kg received 40 mL (mirabegron 80 mg),
50 mL (100 mg), 55 mL (110 mg), or 65 mL (130 mg),
respectively. The doses were predicted using an adult
population PK model with allometric scaling to result in
exposures equivalent to those in adults at steady state
following once-daily mirabegron 25 or 50 mg dosing. The
target exposures (area under the concentrationetime curve
over a dosing interval [AUCtau]) were 69 ng$h/mL (low dose)
and 188 ng$h/mL (high dose), respectively (Astellas, data
on file). The model accounted for food intake (mirabegron
bioavailability is greater under fasted conditions [23]) and
also the 48% relative bioavailability of the oral suspension
to the tablet previously demonstrated in adults (Astellas,
data on file). The accumulation for a 24-h repeat dosing
interval is w 2-fold higher than following a single dose [24],
so the doses were multiplied by two to achieve steady-state
exposures.
Patients were allowed a light lunch (low in fat and
fiber) >2 h after dosing in cohorts 1e4 and 6, and >4 h after
dosing in cohort 5. Food or ingredients that may impact the
absorption of mirabegron (high fat or fiber foods, chewing
gum, or citrus fruit) were not permitted.
Independent ethics committee approval was obtained
before starting the studies, which were conducted in
accordance with Good Clinical Practice, International
Committee on Harmonisation guidelines, and the ethical
principles originating from the Declaration of Helsinki.
Informed consent was provided by patients and/or their
parents/legal guardians. Informed consent/assent was
provided according to local law.Assessments
Screening assessments included demographics, medical and
OAB/NDO history, prior/concomitant medications, vital
signs, electrocardiograms (ECGs), safety laboratory evalu-
ations, and adverse events (AEs). Patients underwent 24-h
Holter monitoring on a reference day (day 4 to 1,
baseline) and on day 1 (before dosing).
Blood samples for PK analysis were obtained from each
child (six samples) or adolescent (seven samples). Samples
were taken on day 1 (0.5e2, 3e5, and 6e8 h after dosing
for children; 0.5e2, 3e4, 5e6, and 7e8 h after dosing for
adolescents), day 2 (24e32 h), and on another 2 days be-
tween days 3 and 7 (48e56, 72e80, 96e104, 120e128, or
144e152 h).
The occurrence and severity of AEs (classified using
Medical Dictionary for Regulatory Affairs v16.0) were
assessed throughout both studies. AEs of special interestincluded increased blood pressure (BP), tachycardia, QT
prolongation, hypersensitivity reactions, cardiac
arrhythmia, cardiovascular AEs, urinary retention, hepato-
toxicity, and nervous system AEs (seizure, syncope). Safety
laboratory evaluations (hematology, biochemistry, urinaly-
sis) were conducted before dosing on day 1, on day 2, and
at end of study (EoS) (assessment conducted during the last
PK sample visit). Furthermore, 12-lead ECGs were con-
ducted before and 1, 2, 4, and 6 h after dosing on day 1,
and at EoS. Vital signs were assessed before dosing and 1, 2,
4, and 6 h after dosing on day 1, on day 2, and at EoS.
Potentially clinically significant (PCS) criteria for study 1
were systolic BP (SBP) above the 95th age/sex/height
percentile and 20 mmHg change from baseline, diastolic
BP (DBP) above the 95th age/sex/height percentile and
15 mmHg change from baseline, and pulse rate above the
95th age/sex percentile and 15 bpm change from base-
line. The same criteria were used for study 2, but with the
99th age/sex/height percentiles. Postvoid residual (PVR)
volume was assessed in patients with idiopathic OAB by
ultrasonography/bladder scan before dosing and 5 h after
dosing. PVR volume was not assessed in patients with NDO
as all were on clean intermittent catheterization.
A palatability and acceptability questionnaire using a
visual analog scale was completed by the patient (or
parent/guardian based on patient input) after tablet and
suspension dosing. This exploratory endpoint was added as
a protocol amendment to study 1, and therefore was not
conducted for all patients.Statistical methods
Six patients per cohort were expected to receive study
drug, consistent with Food and Drug Administration guid-
ance [17,19]. If six patients tolerated the dose, the lower
limit of Clopper-Pearson 95% confidence interval (CI) for
the dose tolerability rate would have been >60%, thereby
supporting the statement that 60% of individuals taking
the same dose under the same conditions would tolerate
the dose. For the nine patients planned for inclusion in
study 2, the lower limit of the 95% CI would be >70%.
The safety analysis set consisted of all patients who took
study medication. The PK analysis set consisted of all pa-
tients who received study drug and who had concentration
values for a sufficient number of time points to reliably
calculate at least one PK parameter.
Patient demographic data were summarized with
descriptive statistics using SAS version 9.3 or higher (Cary,
NC, USA).
A preliminary population PK model developed from data
on mirabegron PK in adults (including food, dose, and
formulation effects on bioavailability) adequately
described the PK of mirabegron in adults after administra-
tion of the suspension and tablets under fed and fasted
conditions. Weight (allometric scaling) was added to the PK
parameters to provide scale for the pediatric patients and
determine the doses to use. The model was later updated
by pooling the adult and pediatric data and re-estimating
the model parameters. The following parameters were
estimated or derived using population PK modeling (NON-
MEM 7.3; ICON Development Solutions, Ellicott City, MD,
31.e4 S. Rittig et al.USA): the apparent oral plasma clearance (CL/F), area
under the concentrationetime curve from 0 to 24 h
(AUC24), the area under the concentrationetime curve from
0 to infinity (AUCinf), and the half-life (t1/2). The maximum
concentration of drug after administration (Cmax) and the




Forty-three patients received treatment and completed the
studies (Supplementary Fig. 2). Patient demographic and
baseline characteristics are shown in Table 1. Most patients
across both studies were female (28/43, 65.1%), and the
race of all patients was white. The mean ages of the chil-
dren and the adolescents were 8.1 years (range 7e10 years
in study 1; 4e10 years in study 2) and 14.5 years (range
12e17 years), respectively. In total, 26 patients (60.5%) had
idiopathic OAB and 17 (39.5%) had NDO. For patients with
NDO, spina bifida with closure surgery was the most com-
mon neurological condition and almost all were receiving
antimuscarinic and/or mirabegron treatment at screening
(94.1%).
Pharmacokinetics
Observed and model-predicted mirabegron plasma con-
centrations are shown in Fig. 1. Median AUC24 values (Table
2) were typically within the range of the adult steady-state
values obtained during dosing with once-daily tablets of
mirabegron 25 and 50 mg (Astellas, data on file). Although
the median AUC24 values in patients who received low-dose
tablets (fed conditions) or high-dose tablets or oral sus-
pension (fed conditions) were not identical to the target
values of 69 and 188 ng$h/mL, respectively, they were
within range, and the span of individual values for each
cohort included the target value. Conversely, the median
AUC24 values for children who received high-dose tablets
(fasted conditions) were higher than the target value
(median: 424 ng$h/mL, range: 348e577 ng$h/mL). Median
tmax and t1/2 values were similar across all cohorts
(approximately 4e5 and 42e45 h, respectively).
Children who received high-dose oral suspension had
higher median AUC24, AUCinf, and CL/F values, and a lower
median Cmax than children who received high-dose tablets
(fed conditions). Median Cmax and CL/F values were higher
and lower, respectively, in children than in adolescents
within each tablet category (low and high dose, fed con-
ditions). For the children who received high-dose tablets,
median AUC24, AUCinf, and Cmax values were higher and
median CL/F values were lower for the patients dosed
under fasted conditions compared with the patients dosed
under fed conditions.
Safety and tolerability
Overall, five patients developed treatment-emergent AEs
(TEAEs), all of which were mild in severity and did notrequire treatment (Table 3). No serious AEs were reported,
and no patients discontinued because of an AE. Of the AEs
of special interest, only ECG QT prolongation was reported
in one child (cohort 2) and one adolescent (cohort 3).
There were no clinically relevant changes in vital signs in
either study. Two patients met the PCS criteria for changes
in SBP and DBP. Increases in mean pulse rate relative to
baseline were observed across all cohorts, with nine pa-
tients meeting the PCS criteria. There were no clinically
relevant changes in average heart rate relative to dosing
time observed during the 24-h Holter measurements.
No clinically relevant changes in PVR volume were
observed, and no post-dose PVR volumes were significantly
elevated (exceeded the 20 mL threshold defined by the
ICCS [2]).
Palatability and acceptability
There were no reports of bad taste or swallowing diffi-
culties for the tablets, although some children found the
oral suspension unpleasant (Supplementary Table 2).
Discussion
The phase 1 studies reported herein represent the first in-
vestigations evaluating mirabegron PK in pediatric patients.
As well as focusing on the PK, this investigation also
examined the safety, tolerability, and palatability/accept-
ability of the mirabegron tablet and oral suspension for-
mulations used.
The single weight-based pediatric tablet and oral sus-
pension doses selected using the preliminary population PK
model were capable of generating exposures close to the
target exposures in adults at steady state, which helped
confirm that the model constructed from adult data could
be successfully used to predict pediatric dosing. The
higher-than-target exposures observed in children who
received high-dose tablets under fasted conditions may be
explained by the exposure targets being more relevant to
the fed than fasted state, as during the studies on which
the population PK model was based, patients were either
fed or given no instructions regarding food.
The preliminary population PK model was updated with
the data from these studies to characterize mirabegron PK
in pediatric patients. Apparent oral plasma clearance was
higher in children who received high-dose oral suspension
versus high-dose tablets under fed conditions, a finding
which is consistent with the lower relative bioavailability of
the oral suspension to the tablet that has been previously
demonstrated in adults (Astellas, data on file). The lower
CL/F values in children compared with adolescents in co-
horts that received the same dose level and fed state were
expected because of clearance being related to body
weight, as demonstrated by allometric scaling principles.
The higher exposure and lower CL/F in the cohort of chil-
dren who received high-dose tablets under fasted condi-
tions versus fed conditions are consistent with the
increased bioavailability of mirabegron in the fasted versus
fed state previously confirmed in adults [23].
The Cmax data obtained are difficult to interpret as
sampling was sparse during the absorption phase and,
Table 1 Demographics and baseline characteristics (safety analysis set).






































Male 2 (28.6) 2 (28.6) 2 (25.0) 2 (33.3) 3 (50.0) 4 (44.4)
Female 5 (71.4) 5 (71.4) 6 (75.0) 4 (66.7) 3 (50.0) 5 (55.6)
Age in years
Mean  SD 14.9  1.6 8.1  0.9 14.1  1.6 8.2  0.8 9.3  0.8 7.3  2.2
Median 15.0 8.0 14.5 8.0 9.5 8.0
Range 13e17 7e9 12e16 7e9 8e10 4e10
Weight at day 1 (predose) in kg
Mean  SD 51.0  7.5 31.2  5.4 55.3  14.0 26.7  4.8 31.3  5.3 26.0  8.8
Median 50.2 31.7 53.3 25.4 30.3 25.0
Range 43.0e66.6 21.0e37.8 36.9e80.0 22.0e35.7 25.1e41.0 15.9e44.4
Height at screening in cm
Mean  SD 162.6  8.3 133.9  9.7 160.4  10.4 131.6  8.0 136.2  8.8 125.8  13.8
Median 164.0 135.3 157.5 131.3 135.3 130.0
Min-max 151.5e175.0 116.0e148.0 150.0e175.0 123.0e144.0 126.7e150.0 104.0e145.0
Diagnosis at screening, n (%)
NDO 2 (28.6) 2 (28.6) 3 (37.5) 2 (33.3) 2 (33.3) 6 (66.7)
Idiopathic OAB 5 (71.4) 5 (71.4) 5 (62.5) 4 (66.7) 4 (66.7) 3 (33.3)
OAB/NDO medication
at screening, n (%)















1 mirabegron + solifenacin;
1 oxybutynin)
OAB 0/5 1/5 (Tolterodine +
desmopressin)




25.8  34.6 23.5  13.5 53.3  32.5 32.6  10.5 32.2  13.3 25.2  22.5






































Table 1 (continued )





































Medical condition of patients with NDO, n (%)b
Spina bifida with
closure surgery
1 (14.3) 1 (14.3) 2 (25.0) 2 (33.3) 2 (33.3) 5 (55.6)
Sacral
agenesis/hypoplasia
e 1 (14.3)c e e e 1 (11.1)c
Syringomyelia e e e e e 1 (11.1)c
Congenital
system anomaly
1 (14.3) e e e e e
Tethered cord
syndrome
e 1 (14.3)c e e e e
Myelitis transversa e e 1 (12.5) e e e
In study 1, one patient in cohort 3 and two patients in cohort 5 deviated from the protocol. The patient in cohort 3 received a lower dose of mirabegron than defined by the protocol based
on her weight, and the two patients in cohort 5 had higher heart rate than permitted by the exclusion criteria. A further six protocol deviations were noted after hard lock of the database.
Four patients had mean SBP greater than the 95th percentile at screening according to age and height. Two patients had pulse rate >100 bpm at screening. The data from the patients with
protocol deviations were not excluded and are not considered to have impacted the overall results/conclusions. There were no protocol deviations in study 2 (cohort 6).
NDO Z neurogenic detrusor overactivity, OAB Z overactive bladder, SBP Z systolic blood pressure, SD Z standard deviation.
a Among patients with idiopathic OAB.














fed conditions (n = 7)
Cohort 2
Children, low‐dose tablets,
fed conditions (n = 7)
Cohort 3
Adolescents high‐dose tablets,
fed conditions (n = 8)
Cohort 4
Children, high‐dose tablets,
fed conditions (n = 6)
Cohort 5
Children, high‐dose tablets,
fasted conditions (n = 6)
Cohort 6
Children, high‐dose oral suspension,
fed conditions (n = 9)































































Fig. 1 Observed and model-predicted plasma concentrations of mirabegron (pharmacokinetics analysis set). Data shown are
individual observed concentrations (points) and model-predicted concentrations (dashed lines). Cohorts 1e5 were from study 1,
and cohort 6 was from study 2.
Table 2 Pharmacokinetic parameters of mirabegron by cohort (pharmacokinetics analysis set).





































AUCinf, ng$h/mL 103 (83.7e158) 117 (80.6e208) 411 (150e573) 422 (288e715) 883 (724e1200) 537 (199e670)
Cmax, ng/mL
a 3.85 (2.45e10.5) 5.24 (2.45e14.9) 29.7 (3.40e80.4) 38.1 (14.1e98.2) 58.4 (28.6e79.2) 16.7 (2.56e42.4)
tmax, h
a 5.03 (3.95e5.75) 4.17 (2.55e6.37) 4.48 (3.08e7.08) 4.28 (3.88e4.42) 3.95 (3.47e4.27) 3.93 (1.25e6.50)
t1/2, h 45.0 (41.1e48.7) 44.5 (40.7e50.1) 42.7 (40.5e54.0) 42.2 (39.3e45.2) 43.0 (42.0e52.9) 42.7 (39.4e65.2)
CL/F, L/h 248 (158e320) 214 (120e310) 158 (131e333) 118 (70.0e174) 59.2 (41.7e97.7) 186 (146e502)
AUC24, ng$h/mL 49.7 (40.2e76.1) 56.3 (38.8e100) 198 (72.2e275) 203 (138e344) 424 (348e577) 258 (95.7e322)
Data shown are median (range).
AUC24 Z area under the concentrationetime curve from 0 to 24 h, AUCinf Z area under the concentrationetime curve from 0 to infinity,
CL/F Z apparent oral plasma clearance, Cmax Z maximum concentration of drug after administration, tmax Z time at which Cmax
occurred, t1/2 Z half-life.
a Cmax and tmax are observed, all other parameters are model based.
The pharmacokinetics of mirabegron in children and adolescents 31.e7
Table 3 Treatment-emergent adverse events (safety analysis set).





































TEAE, n (%) 1 (14.3) 1 (14.3) 1 (12.5) 0 1 (16.7) 1 (11.1)
Drug-related TEAE, n (%) 0 0 1 (12.5) 0 0 0
TEAE details Pyrexia, vomiting ECG QT prolongeda ECG QT prolongedb N/A Vomiting Pyrexia
AE Z adverse event, ECG Z electrocardiogram, N/A Z not applicable, OAB Z overactive bladder, QTcB Z QT interval corrected for
heart rate by Bazett’s formula, QTcF Z QT interval corrected for heart rate by Fridericia’s formula, TEAE Z treatment-emergent AE.
a A 9-year-old female with idiopathic OAB receiving mirabegron 25 mg by tablet experienced a mean QTcB >450 ms 4 h after dosing.
This event was deemed to be not related to study drug by the investigator.
b A 15-year-old female with idiopathic OAB receiving mirabegron 75 mg by tablet. The ECG showed a mean increase of QTcB >30 ms
versus baseline at 4 h after dosing (448.33 versus 407.83 ms, respectively) which was considered to be clinically significant by the
investigator. The mean QTcF increased 29.4 ms versus baseline at 4 h after dosing (432.7 versus 403.3 ms, respectively). This AE was
considered to be possibly drug-related by the investigatordthe only TEAE to be deemed so in either study.
31.e8 S. Rittig et al.consequently, there was high variation between patients.
In addition, the Cmax values observed after administration
of the single doses during the present studies would be
higher than during normal daily dosing, as higher single
doses were administered to target steady-state exposures
and account for the accumulation that occurs at steady
state. Tmax and t1/2 values were consistent across all co-
horts at approximately 4e5 and 42e45 h, respectively,
which are similar to the values obtained during a single-
dose adult PK study [25].
The final population PK model, updated with the pedi-
atric data from these studies, will be used to develop a
weight-based dosing algorithm for future studies with pe-
diatric patients. In addition, as adult dosing is often
appropriate for adolescents [26], the model can also be
used to determine a body-weight cutoff above which an
adult dose is appropriate.
Mirabegron was well tolerated at the tested doses, with
only one TEAE that was considered to be drug related. This
adolescent, who received a high dose of mirabegron under
fed conditions, experienced QT prolongation (QT interval
corrected for heart rate by Bazett’s formula [QTcB] in-
crease >30 ms from baseline at 4 h after dosing). Given the
high variability between patients and restrictive definitions
for change, the authors consider that this result was not of
clinical importance. Furthermore, the corresponding mean
increase in QT interval corrected for heart rate by Frider-
icia’s formula did not meet the criteria for QTc interval
change (29.4 ms from baseline to 4 h after dosing). This is
consistent with the fact that the QTcB method is known to
overestimate the duration of cardiac repolarization at high
heart rates [27]. During a thorough, four-arm, two-way
crossover, active- and placebo-controlled study with 352
randomized healthy adults, daily dosing of mirabegron 50 or
100 mg (supratherapeutic dose) did not cause any relevant
prolongations in individual subject-specific corrected QT
intervals [28]. The higher mirabegron exposures in children
who received high-dose tablets under fasted conditions did
not result in any additional safety issues compared with
dosing under fed conditions.Increases in mean pulse rate were consistently observed
for all cohorts and nine (20.9%) patients met the PCS
criteria for pulse rate. It is difficult to draw any meaningful
conclusions about the clinical significance of these findings
because of the burdensome study design (e.g. clinic visits,
numerous blood draws, and fasted conditions for cohort 5),
the lack of a placebo group, the low number of patients,
and the high data variability. Additional studies involving
placebo groups may be required to determine the clinical
significance of these results, although previous mirabegron
studies involving pediatric patients with OAB have not re-
ported any clinically significant changes in vital signs
[11,13].
Limitations of these two single-dose studies include the
lack of a placebo group which, although would have added
perspective to the safety and tolerability data, was not
possible due to the ethical considerations of taking
frequent blood draws for PK analysis from patients who did
not receive any drug. By design, the number of patients
was low, although there were particularly few with NDO.
This is unsurprising, given the low prevalence of NDO,
which likely reflects the reducing frequency of neural tube
defects [29].Conclusions
These data represent the first investigation of mirabegron
PK in pediatric patients. Overall, a population PK model
based on adult exposure data successfully predicted the
single, weight-adjusted pediatric doses required to achieve
drug exposures comparable with steady state in adults
during daily treatment. The final population PK model,
updated with the PK data from these studies, will be a
suitable foundation for a weight-based pediatric dosing
algorithm for use in future studies. The results of this
investigation also showed that mirabegron had a favorable
safety profile and satisfactory palatability/acceptability.
The ongoing phase 3 study in pediatric patients with NDO
will collect additional PK data, as well as determine the
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